The bone-vascular axis in chronic kidney disease

Current Opinion in Nephrology and Hypertension

Volumn 19, Issue 4, 2010, Pages 349-353

  Demer, Linda ^a   Tintut, Yin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

calcification; kidney; osteodystrophy; vascular

Indexed keywords

ALKALINE PHOSPHATASE; AUTOTAXIN; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; FIBROBLAST GROWTH FACTOR 23; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MATRIX EXTRACELLULAR PHOSPHOGLYCOPROTEIN; OSTEOCALCIN; OSTEOGENIC PROTEIN 1; OSTEOPROTEGERIN; PARATHYROID HORMONE; PHOSPHODIESTERASE I; SELECTIVE ESTROGEN RECEPTOR MODULATOR; WARFARIN;

AORTA; BLOOD VESSEL CALCIFICATION; BONE DENSITY; CHRONIC KIDNEY DISEASE; HEMODIALYSIS; HYPERPARATHYROIDISM; HYPERPHOSPHATEMIA; KIDNEY FAILURE; LIPID OXIDATION; METABOLIC BONE DISEASE; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; ANIMAL; BLOOD VESSEL; BONE; DISEASE MODEL; DRUG EFFECTS; HUMAN; KIDNEY FAILURE, CHRONIC; PATHOLOGY;

ANIMALS; BLOOD VESSELS; BONE AND BONES; DISEASE MODELS, ANIMAL; HUMANS; KIDNEY FAILURE, CHRONIC;

EID: 77954086161     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e32833a3d67     Document Type: Review

References (43)

1. Joki N, Hase H, Shiratake M, et al. Calcaneal osteopenia is a new marker for arterial stiffness in chronic hemodialysis patients. Am J Nephrol 2005; 25:196-202.
2. Raggi P, Bellasi A, Ferramosca E, et al. Pulse wave velocity is inversely related to vertebral bone density in hemodialysis patients. Hypertension 2007; 49: 1278-1284.
3. Sumino H, Ichikawa S, Kasama S, et al. Elevated arterial stiffness in postmenopausal women with osteoporosis. Maturitas 2006; 55:212-218.
4. Tomiyama C, Carvalho AB, Higa A, et al. Coronary calcification is associated with lower bone formation rate in CKD patients not yet in dialysis treatment. J Bone Miner Res 2009. [Epub ahead of print]
5. Towler DA. Vascular calcification in ESRD: another cloud appears in the perfect storm-but highlights a silver lining? Kidney Int 2004; 66:2467-2468.
6. MoeS, DruekeT, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69:1945-1953.
7. Moe SM. Vascular calcification and renal osteodystrophy relationship in chronic kidney disease. Eur J Clin Invest 2006; 36 (Suppl 2):51-62.
8. Drueke T, Witko-Sarsat V, Massy Z, et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 2002; 106:2212-2217.
9. Shroff RC, McNair R, Figg N, et al. Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis. Circulation 2008; 118:1748-1757.
10. Kis E, Cseprekal O, Biro E, et al. Effects of bone and mineral metabolism on arterial elasticity in chronic renal failure. Pediatr Nephrol 2009; 24:2413-2420.
11. London GM, Marchais SJ, Guerin AP, et al. Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD. J Am Soc Nephrol 2008; 19:1827-1835.
12. Barreto DV, BarretoFC, Liabeuf S, et al. Plasma interleukin-6 is independently associated with mortality in both hemodialysis and predialysis patients with chronic kidney disease. Kidney Int 2010; 77:550-556.
13. Adragao T, Herberth J, Monier-Faugere MC, et al. Low bone volume: a risk factor for coronary calcifications in hemodialysis patients. Clin J Am Soc Nephrol 2009; 4:450-455.
14. Moe SM, Chen NX, Seifert MF, et al. A rat model of chronic kidney disease mineral bone disorder. Kidney Int 2009; 75:176-184.
15. Zhao LJ, Liu YJ, Liu PY, et al. Relationship of obesity with osteoporosis. J Clin Endocrinol Metab 2007; 92:1640-1646.
16. Benetos A, Zervoudaki A, Kearney-Schwartz A, et al. Effects of lean and fat mass on bone mineral density and arterial stiffness in elderly men. Osteoporos Int 2009; 20:1385-1391.
17. Barreto DV, Barreto FdeC, Carvalho AB, et al. Association of changes in bone remodeling and coronary calcification in hemodialysis patients: a prospective study. Am J Kidney Dis 2008; 52:1139-1150.
18. Skolnick AH, Osranek M, Formica P, Kronzon I. Osteoporosis treatment and progression of aortic stenosis. Am J Cardiol 2009; 104:122-124.
19. Shao JS, Cheng SL, Charlton-Kachigian N, et al. Teriparatide (human parathyroid hormone (1-34)) inhibits osteogenic vascular calcification in diabetic low density lipoprotein receptor-deficient mice. J Biol Chem 2003; 278: 50195-50202.
20. Sebastian EM, Suva LJ, Friedman PA. Differential effects of intermittent PTH(1-34) and PTH(7-34) on bone microarchitecture and aortic calcifica tion in experimental renal failure. Bone 2008; 43:1022-1030.
21. Jean G, Terrat JC, Vanel T, et al. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant 2009; 24:2792-2796.
22. Nasrallah MM, El-Shehaby AR, Salem MM, et al. Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients. Nephrol Dial Transplant 2010. [Epub ahead of print]
23. El-Abbadi MM, Pai AS, Leaf EM, et al. Phosphate feeding induces arterial medial calcification in uremic mice: role of serum phosphorus, fibroblast growth factor-23, and osteopontin. Kidney Int 2009; 75:1297-1307.
24. David V, Martin A, Hedge AM, Rowe PS. Matrix extracellular phosphoglyco-protein (MEPE) is a new bone renal hormone and vascularization modulator. Endocrinology 2009; 150:4012-4023.
25. Mathew S, Davies M, Lund R, et al. Function and effect of bone morphoge-netic protein-7 in kidney bone and the bone-vascular links in chronic kidney disease. Eur J Clin Invest 2006; 36 (Suppl 2):43-50.
26. Freedman BI, Bowden DW, Ziegler JT, et al. Bone morphogenetic protein 7 (BMP7) gene polymorphisms are associated with inverse relationships be tween vascular calcification and BMD: the Diabetes Heart Study. J Bone Miner Res 2009; 24:1719-1727.
27. Parhami F, Morrow AD, Balucan J, et al. Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation: a possible explanation for the paradox of arterial calcification in osteoporotic patients. Arterioscler Thromb Vasc Biol 1997; 17:680-687.
28. Tintut Y, Parhami F, Tsingotjidou A, et al. 8-Isoprostaglandin E2 enhances receptor-activated NFkappa B ligand (RANKL)-dependent osteoclastic potential of marrow hematopoietic precursors via the cAMP pathway. J Biol Chem 2002; 277:14221-14226.
29. Graham LS, Parhami F, Tintut Y, et al. Oxidized lipids enhance RANKL production by T lymphocytes: implications for lipid-induced bone loss. Clin Immunol 2009; 133:265-275.
30. Tintut Y, Demer L. Role of osteoprotegerin and its ligands and competing receptors in atherosclerotic calcification. J Investig Med 2006; 54:395-401.
31. Abedin M, Omland T, Ueland T, et al. Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study). Am J Cardiol 2007; 99:513-518.
32. Morena M, Dupuy AM, Jaussent I, et al. A cut-off value of plasma osteoprotegerin level may predict the presence of coronary artery calcifications in chronic kidney disease patients. Nephrol Dial Transplant 2009; 24:3389-3397.
33. Morony S, Tintut Y, Zhang Z, et al. Osteoprotegerin inhibits vascular calcifica-tion without affecting atherosclerosis in ldlr(\/\) mice. Circulation 2008;117:411-420.
34. Rutsch F, Vaingankar S, Johnson K, et al. PC-1 nucleoside triphosphate pyrophosphohydrolase deficiency in idiopathic infantile arterial calcification. Am J Pathol 2001; 158:543-554.
35. Johnson K, Goding J, Van Etten D, et al. Linked deficiencies in extracellular PP(i) and osteopontin mediate pathologic calcification associated with defective PC-1 and ANK expression. J Bone Miner Res 2003; 18:994-1004.
36. Babij P, Roudier M, Graves T, et al. New variants in the Enpp1 and Ptpn6 genes cause low BMD, crystal-related arthropathy, and vascular calcification. J Bone Miner Res 2009; 24:1552-1564.
37. Fahrleitner-Pammer A, Herberth J, Browning SR, et al. Bone markers predict cardiovascular events in chronic kidney disease. J Bone Miner Res 2008; 23:1850-1858.
38. Price PA, Faus SA, Williamson MK. Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. Arterioscler Thromb Vasc Biol 1998; 18:1400-1407.
39. Barnes C, Newall F, Ignjatovic V, et al. Reduced bone density in children on long-term warfarin. Pediatr Res 2005; 57:578-581.
40. Koos R, Krueger T, Westenfeld R, et al. Relation of circulating matrix Glaprotein and anticoagulation status in patients with aortic valve calcification.Thromb Haemost 2009; 101:706-713.
41. Ashman N, Banerjee A, Yaqoob MM. Statins do not affect mineral metabolism in chronic kidney disease: a retrospective analysis. Nephron Clin Pract 2009; 111:c236-c239.
42. Lomashvili KA, Monier-Faugere MC, Wang X, et al. Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failure. Kidney Int 2009; 75:617-625.
43. Moe SM, Seifert MF, Chen NX, et al. R-568 reduces ectopic calcification in a rat model of chronic kidney disease-mineral bone disorder (CKD-MBD). Nephrol Dial Transplant 2009; 24:2371-2377.